- Home
- TDUP vs PLRX Comparison
TDUP vs PLRX Comparison
Compare TDUP & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TDUP
- PLRX
- Stock Information
- Founded
- TDUP 2009
- PLRX 2015
- Country
- TDUP United States
- PLRX United States
- Employees
- TDUP N/A
- PLRX N/A
- Industry
- TDUP Catalog/Specialty Distribution
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- TDUP Consumer Discretionary
- PLRX Health Care
- Exchange
- TDUP Nasdaq
- PLRX Nasdaq
- Market Cap
- TDUP 172.9M
- PLRX 165.5M
- IPO Year
- TDUP 2021
- PLRX 2020
- Fundamental
- Price
- TDUP $2.56
- PLRX $3.08
- Analyst Decision
- TDUP Buy
- PLRX Buy
- Analyst Count
- TDUP 5
- PLRX 10
- Target Price
- TDUP $3.50
- PLRX $14.86
- AVG Volume (30 Days)
- TDUP 796.1K
- PLRX 3.4M
- Earning Date
- TDUP 03-03-2025
- PLRX 02-26-2025
- Dividend Yield
- TDUP N/A
- PLRX N/A
- EPS Growth
- TDUP N/A
- PLRX N/A
- EPS
- TDUP N/A
- PLRX N/A
- Revenue
- TDUP $313,757,000.00
- PLRX N/A
- Revenue This Year
- TDUP N/A
- PLRX N/A
- Revenue Next Year
- TDUP N/A
- PLRX N/A
- P/E Ratio
- TDUP N/A
- PLRX N/A
- Revenue Growth
- TDUP 0.58
- PLRX N/A
- 52 Week Low
- TDUP $0.50
- PLRX $2.43
- 52 Week High
- TDUP $2.99
- PLRX $18.00
- Technical
- Relative Strength Index (RSI)
- TDUP 56.98
- PLRX 22.51
- Support Level
- TDUP $2.37
- PLRX $2.92
- Resistance Level
- TDUP $2.99
- PLRX $3.16
- Average True Range (ATR)
- TDUP 0.23
- PLRX 0.85
- MACD
- TDUP -0.01
- PLRX -0.39
- Stochastic Oscillator
- TDUP 54.26
- PLRX 6.22
About TDUP ThredUp Inc.
ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app, and RaaS partners. Geographically, the majority of the company's revenue is generated from United States.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.